A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (liquid injectable emulsion, USP) 20% or Standard-of-Care soybean Oil-Based Lipid Emulsion

About this Study

To evaluate the risk of developing EFAD in pediatric patients, including neonates, receiving either Clinolipid or standard-of-care soybean oil-based lipid emulsion (Intralipid) as a component of parenteral nutrition (PN) within the hospital setting from 7 to 90 days, inclusive.

Sponsor Protocol ID:6344-001
IRB Number:2020V0315
Actively Enrolling
Interventional
Phase 4
July 01, 2021
Eligibility Criteria
Both Male and Female
No
Yes
No

Inclusion Criteria1.Patients who are expected to require PN for at least 7 days; 

2. Premature infants (born at 24 to

3. A patient, or legal representative, has signed a written informed consent form per 21 CFR Part 50.55(e).

Exclusion Criteria1. Patients who are not expected to survive hospitalization or with a severe critical unresponsive illness at time of initiation with foreseeable intercurrent events that could jeopardize the patient’s participation in the study (i.e. unresponsive shock, sepsis, renal failure requiring dialysis, severe unresponsive metabolic acidosis, and/or severe unresponsive metabolic disorders), as judged by the Investigator; 

2. Patients with a known hypersensitivity to lipid emulsion, egg or soybean proteins, or any of the active substances, excipients, or components of the container or who have a history of an adverse event due to ILE; 

3. Patients with liver disease including cholestasis 

4. Patients with severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (i.e. triglyceride >400 mg/dL); 

5. Premature infants born

6. Patient requires or is expected to require propofol for sedation; 

7. Patient has received a diagnosis of COVID-19 (diagnosis

8. Female patients who are pregnant. Note: All female patients ≥12 years of age must have a negative urine human chorionic gonadotropin (hCG) pregnancy test at screening. For female patients

Categories Click category to view its trials.
Pediatrics
Participating Locations
Children's of Mississippi Hospital - Kathy and Joe Sanderson Tower
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Sandra Tyler
Phone Number: 601-496-8133
Email: sltyler@umc.edu
Principal Investigator:Bhatt, Abhay, M.D.
How to participate in our Clinical Trials